BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Table 3 Relationship between BIRC3 and clinical pathology in human epidermal growth factor receptor 2 (+) group, n (%)

	BIRClow group (n = 7)	BIRChigh group (n = 21)	P value
Sex (male)	6 (85.7)	19 (90.5)	1.000
Age (year)	63.71 ± 8.45	63.95 ± 8.52	0.9492
BMI (kg/m2)	22.94 ± 2.81	24.56 ± 3.40	0.2702
Tumor size (cm)	3.64 ± 2.34	4.90 ± 1.78	0.1462
Differentiation			0.4291
Poor	3 (42.9)	14 (66.7)
Moderate	4 (50.0)	6 (28.6)
High	0 (0.0)	1 (4.8)
T stage			0.030
1	1 (14.3)	0 (0)
2	2 (28.6)	2 (9.5)
3	4 (57.1)	2 (9.5)
4	0 (0.0)	17 (81.0)
N stage			0.245
0	3 (42.9)	5 (23.8)
1	2 (28.6)	9 (42.9)
2	2 (28.6)	3 (14.3)
3	0 (0.0)	4 (19.0)
M stage			-
0	7 (100.0)	19 (90.5)
1	0 (0.0)	2 (9.5)
TNM stage			0.016
I	1 (4.8)	0 (0.0)
II	2 (9.5)	0 (0.0)
III	4 (19)	19 (90.5)
IV	0 (0.0)	2 (9.5)
Survival			0.5711
Live	6 (85.7)	11 (52.4)
Dead	1 (14.3)	10 (47.6)
OS (month)
mean ± SD	31.43 ± 7.138	17.0 ± 8.63	0.0012
Median (range)	29 (22-43)	14 (8-45)	-
Recurrence			0.5711
No	6 (85.7)	10 (47.6)
Recurrence	1 (14.3)	11 (52.4)
DFS (month)
mean ± SD	24.14 ± 4.34	14.76 ± 9.89	0.0022
Median (range)	25 (17-29)	13 (2-45)	-

¹P calculated by fisher test.

²P calculated by t text.

BMI: Body mass index; TNM: Tumor node metastasis; OS: Overall survival; DFS: Disease-free survival.